Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
KOS-1584 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Single Arm 25mg/m2 | EXPERIMENTAL | KOS-1584 25mg/m2 |
| Name | Type | Description |
|---|---|---|
| KOS-1584 | DRUG | 25 mg/m2, IV (in the vein) on day 1 and 8 of each 21 day cycle until progression or unacceptable toxicity develops. |
Inclusion Criteria: * Histologically or cytologically proven NSCLC, Stage IIIB or Stage IV. * Eligible patients must have received only one prior chemotherapy regime for Stage IIIB/IV NSCLC. * Good performance status. Exclusion Criteria: * Prior treatment with an epothilone. * Known central nervo...
Top 20 of 84 competitors
KOS-1584 is an investigational small molecule being studied for the treatment of Non-Small Cell Lung Cancer (NSCLC). It is intended for patients with advanced or metastatic Stage IIIB/IV disease. The drug is currently in clinical development and has not been approved by regulatory authorities.
KOS-1584 is being developed by Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker symbol BMY. The company is conducting clinical research to evaluate the drug's safety and efficacy in patients with Non-Small Cell Lung Cancer.
KOS-1584 is in Phase 2 clinical development. It is an investigational drug and has not been approved for any use. The Phase 2 study has been completed, and the drug remains under evaluation for the treatment of Non-Small Cell Lung Cancer.
KOS-1584 has one completed clinical trial, identified as NCT00651508. This Phase 2 study evaluated the drug in patients with advanced or metastatic Stage IIIB/IV Non-Small Cell Lung Cancer. The trial was conducted in the United States and enrolled adult patients of all sexes.
KOS-1584 is a small molecule therapeutic being studied for Non-Small Cell Lung Cancer. Its specific molecular target has not been disclosed in available information, so the exact mechanism of action is not publicly detailed.